Travere Therapeutics, Inc.TVTXNASDAQ
Loading
Year-over-year free cash flow growth rate
Latest
330.65%
↑ 120% vs avg
Percentile
P97
Near historical high
Streak
3 qtr
Consecutive growthAccelerating
Average
-1633.23%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 330.65% |
| Q3 2025 | 198.59% |
| Q2 2025 | 108.80% |
| Q1 2025 | -19.21% |
| Q4 2024 | 10.69% |
| Q3 2024 | 2.94% |
| Q2 2024 | 58.37% |
| Q1 2024 | -65.09% |
| Q4 2023 | -28.51% |
| Q3 2023 | 18.42% |
| Q2 2023 | 33.54% |
| Q1 2023 | -99.53% |
| Q4 2022 | -38.27% |
| Q3 2022 | -7.37% |
| Q2 2022 | 39.22% |
| Q1 2022 | -88.88% |
| Q4 2021 | -201.14% |
| Q3 2021 | 1348.79% |
| Q2 2021 | 106.12% |
| Q1 2021 | 69.64% |
| Q4 2020 | -65316.67% |
| Q3 2020 | 98.35% |
| Q2 2020 | 67.75% |
| Q1 2020 | -667.30% |
| Q4 2019 | 76.00% |
| Q3 2019 | 18.49% |
| Q2 2019 | 8.07% |
| Q1 2019 | -229.32% |
| Q4 2018 | 4.04% |
| Q3 2018 | -19.25% |
| Q2 2018 | 71.75% |
| Q1 2018 | -505.96% |
| Q4 2017 | -299.26% |
| Q3 2017 | -19.83% |
| Q2 2017 | 133.49% |
| Q1 2017 | 35.50% |
| Q4 2016 | -662.07% |
| Q3 2016 | 16.15% |
| Q2 2016 | 127.31% |
| Q1 2016 | -44.30% |